Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 17/20 | 1.00 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.44 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.44 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lamifiban SCHEMBL4683 | 1.00 | ITGB3 (1.00) | ITGB3ITGA2BF2PLGPRSS1 | |
| SCHEMBL7282972 | 0.92 | ITGB3 (0.86) | ITGB3ITGA2BF2PRSS1 | |
| SCHEMBL7159286 | 0.91 | ITGB3 (0.83) | ITGB3ITGA2BF2PLGPRSS1 | |
| SCHEMBL7285135 | 0.90 | ITGB3 (0.82) | ITGB3ITGA2BF2PLGPRSS1 | |
| SCHEMBL7284586 | 0.90 | ITGB3 (0.82) | ITGB3ITGA2BCYP51A1CA1CA2 | |
| SCHEMBL8382276 | 0.90 | ITGB3 (0.82) | ITGB3ITGA2BCYP51A1CA1CA2 | |
| SCHEMBL7292028 | 0.90 | ITGB3 (0.82) | ITGB3ITGA2BF2PLGCYP51A1 | |
| SCHEMBL7284349 | 0.90 | ITGB3 (0.82) | ITGB3ITGA2BF2PLGCYP51A1 | |
| SCHEMBL13933091 | 0.90 | ITGB3 (0.83) | ITGB3ITGA2BF2PLGPRSS1 | |
| SCHEMBL8383672 | 0.89 | ITGB3 (0.80) | ITGB3ITGA2BCYP51A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946178-A4 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE | MERCK & CO INC (US) | 2003-05-07 | — | — | EP | claimed |
| EP-0939900-A4 | DETECTION OF ANTAGONIST-DEPENDENT GPIIb/IIIa RECEPTOR ANTIBODIES | MERCK & CO INC (US) | 2003-01-08 | — | — | EP | claimed |
| US-20010036913-A1 | Combination therapy for reducing the risks associated with cardiovascular disease | GOULD ROBERT J (US) | 2001-11-01 | — | — | US | claimed |
| US-6235706-B1 | Combination therapy for reducing the risks associated with cardiovascular disease | MERCK & CO., INC. | 2001-05-22 | — | — | US | claimed |
| US-6210904-B1 | DIAGNOSING FOR RISK OF THROMOCYTOPENIA BY DETECTING ABSENCE OF ASSOCIATION OF MONOCLONAL ANTIBODY WITH GLYCOPROTEIN IIB/IIA RECEPTOR:GLYCOPROTEIN IIB/IIA RECEPTOR ANTAGONIST COMPLEX | MERCK & CO., INC. | 2001-04-03 | — | — | US | claimed |
| US-6136804-A | ANTIISCHEMIC AGENTS, ANTITHROMBOTIC AGENTS, THROMBOTIC OCCLUSION AND ANTIPLATELET AGENT | MERCK & CO., INC. (US) | 2000-10-24 | — | — | US | claimed |
| US-6063584-A | Anticoagulant test | MERCK & CO., INC. (US) | 2000-05-16 | — | — | US | claimed |
| US-5978698-A | Angioplasty procedure using nonionic contrast media | MERCK & CO., INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0946178-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE | Merck & Co., Inc. (US) | 1999-10-06 | — | — | EP | claimed |
| EP-0939900-A1 | DETECTION OF ANTAGONIST-DEPENDENT GPIIb/IIIa RECEPTOR ANTIBODIES | Merck & Co., Inc. (US) | 1999-09-08 | — | — | EP | claimed |
| WO-1998022821-A1 | DETECTION OF ANTAGONIST-DEPENDENT GPIIb/IIIa RECEPTOR ANTIBODIES | MERCK & CO., INC. (US) | 1998-05-28 | — | — | WO | claimed |
| WO-1998011896-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE | MERCK & CO., INC. (US) | 1998-03-26 | — | — | WO | claimed |
| WO-1997035579-A1 | A METHOD FOR INHIBITING CLOT FORMATION | MERCK & CO., INC. (US) | 1997-10-02 | — | — | WO | claimed |
| EP-2376074-B1 | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2019-03-13 | — | — | EP | disclosed |
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| EP-0928194-A1 | COMPOSITIONS AND METHODS FOR ADMINISTERING INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1999-07-14 | — | — | EP | disclosed |
| US-5900414-A | TOPICAL APPLYING TO EYE | MERCK & CO., INC. (US) | 1999-05-04 | — | — | US | disclosed |
| WO-1999019463-A1 | ANTICOAGULANT TEST | MERCK & CO., INC. (US) | 1999-04-22 | — | — | WO | disclosed |
| WO-1998008518-A1 | COMPOSITIONS AND METHODS FOR ADMINISTERING INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036913-A1 | Combination therapy for reducing the risks associated with cardiovascular disease | HMGCR, PCSK9, APOB | ITGB3 699/4885ITGA2B 740/4885F2 37/4885 |
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | CYP2B6, CYP1A2, CYP2D6 | ITGB3 2339/4885ITGA2B 2056/4885F2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.